Breast cancer progression: insights into multifaceted matrix metalloproteinases by Chabottaux, Vincent & Noël, Agnès
Published in: Clinical & Experimental Metastasis (2007), vol.24, iss.8, pp. 647-656 
Status: Postprint (Author’s version) 
Breast cancer progression: insights into multifaceted matrix 
metalloproteinases 
Vincent Chabottaux & Agnès Noel 
Laboratory of Tumor and Developmental Biology, Center for Experimental Cancer Research (CRCE), Groupe Interdisciplinaire de 
Génoprotéomique Appliquée (GIGA-Research), University of Liege, Tour de Pathologie (B23), Sart-Tilman, Liège 4000, Belgium 
Abstract: The restricted view of matrix metalloproteinases (MMPs) as simple destroyers of extracellular matrix 
components has largely ignored their substantial contribution in many aspects of cancer development and 
metastatic dissemination. Over the last few years, the relevance of MMPs in the processing of a large array of 
extracellular and cell surface-associated proteins has grown considerably. Our knowledge about the complex 
functions of MMPs and how their contribution may differ throughout cancer progression is rapidly expanding. 
These new findings provide several explanations for the lack of success of MMP inhibition in clinical trials. A 
complete understanding of MMP biology is needed before considering them, their substrates or their products as 
therapeutic targets. In this review, we explore the different faces of MMP implication in breast cancer 
progression by considering both clinical and fundamental aspects. 
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Introduction 
Tumorigenesis and cancer progression rely on the acquisition by tumor cells of novel capacities which are shared 
by most if not all cancer types. According to Hanahan and Weinberg, six essential alterations in cellular 
physiology dictate malignant growth: (1) production of autocrine growth signals; (2) insensitivity to growth-
inhibitory signals; (3) escape from apoptosis; (4) limitless replicative potential; (5) sustained angiogenesis and 
(6) tissue invasion and metastatic dissemination [1]. Initially, Matrix Metalloproteinases (MMPs) were claimed 
to be important in late stages of tumor progression by controlling tumor cell migration, invasion and metastasis 
through ECM degradation. However, due to the rapid development of innovative biochemical techniques [2-4] 
and the expanding use of transgenic and knockout mice [5, 6], it became obvious that the action of MMPs is not 
restricted to the massive destruction of physiological matrix barriers [7]. MMPs are now viewed as key 
regulators of the multiple cellular functions which dictate malignant growth. Although some MMPs are produced 
by tumor cells (e.g. MMP-7), most MMPs are rather produced by stromal cells and therefore might be 
considered as molecular determinants of the "seed and soil" concept proposed by Paget in 1889 [8]. Breast 
carcinomas are often characterized by a stromal reaction that consists of modifications in the composition of both 
cellular elements (infiltration of fibroblastic cells, endothelial cells and inflammatory cells) and the extracellular 
matrix (ECM) [9, 10]. An expansion of the tumor stroma and an increased deposition of ECM known as 
desmoplasia is often associated to invasive breast carcinomas [11]. Fibroblasts within the tumour stroma have 
acquired a modified phenotype similar to that of fibroblasts observed in wound healing [12]. Such "activated" 
fibroblasts named peritumoral fibroblasts, reactive stromal fibroblasts, carcinoma-associated fibroblasts (CAF) 
or tumor-associated fibroblasts [10, 13] actively control the malignant progression of breast cancers, at least 
through their capability to secrete MMPs. The present review aims at describing the emerging functions of 
MMPs which appear more and more as multifunctional enzymes tightly controlling proteolysis both at the cell 
surface and in the pericellular environment. Using examples of studies performed in animal models of breast 
cancers, we explore the mechanisms of MMP action with a special emphasis on the contribution of stromal 
MMPs. Although of great importance, the contribution of MMP in cancer-associated inflammation will not be 
addressed in this review and reader is referred to previous reviews [14-17]. 
The MMP family 
MMPs are a family of 24 human zinc-binding endopeptidases that can degrade virtually all ECM components, 
release and activate/inactivate a growing number of modulators of cell functions [6, 7, 15, 16]. MMPs are 
multidomain proteins characterised by at least three conserved regions: (1) a zinc binding motif 
(HEXXHXXGXXH) required for proteolytic activity, (2) a propeptide cysteine site (PRCGXPD) whose cysteine 
residue interacts with the zinc ion in the zymogen form and (3) a "methionine turn" (XXMXP) which likely 
maintains the zinc-binding site integrity [15]. The activation of these proteases secreted as zymogens requires an 
amino-terminal cleavage of the pro-domain in the trans golgi network by furin-like convertases or extracellularly 
after their secretion (Fig. 1). The MMP production is precisely regulated at transcriptional and translational 
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levels [18, 19]. Once switched on, MMP proteolytic activity is under the control of various physiological 
inhibitors such as tissue inhibitors of metalloproteinases (TIMPs), the plasma inhibitor α2-macroglobulin and the 
reversion-inducing cysteine-rich protein with Kazal motifs (RECK) [20-22]. Most of the MMPs are secreted as 
soluble enzyme but six of them are membrane-type MMPs (MT-MMPs) which are associated with the cell 
membrane by either a COOH-terminal transmembrane domain (MT1-, MT2-, MT3-, MT5-MMPs) or a 
glycosylphosphatidyl-inositol (GPI) anchor (MT4-, MT6-MMPs) [23] (Fig. 1). MT1-MMP (MMP-14), one of 
the most studied MMPs displays pleiotropic functions during both physiological and pathological processes. 
Although most MMP-knockout mice generated up to now do not present any obvious phenotype without 
challenging, MT1-MMP-deficiency is associated with growth delay and leads to a lethal phenotype after birth [5, 
24, 25]. MT1-MMP activates pro-MMP-2 [26] and pro-MMP-13 [27] and has a very wide range of matrix 
substrates [6, 23, 28]. Activation of pro-MMP-2 by MT1-MMP requires the tissue inhibitor of metalloprotein-
ases-2 (TIMP-2) which acts as an adaptor molecule mediating pro-MMP-2 binding to MT1-MMP [29, 30]. 
An increasing number of in vitro studies, mouse models and human clinical studies demonstrate the implication 
of MMPs in all steps of cancer progression including tumor growth, angiogenesis and metastasis [7, 8, 18]. The 
increasing diversity in both substrates and functions of MMPs makes them central regulators in different steps of 
cancer progression and invasion. Now, some MMPs such as MMP-3, -8, -9, -11, -12, -19 and -26 are expected to 
have dual functions in tumor progression and even in some cases anti-tumor properties [17, 31]. Some of the 
known substrates of MMPs include ECM components, growth factors, chemokines, cytokines, cell surface 
proteins and adhesion molecules [6, 7, 17]. Thanks to the development of novel powerful proteomic techniques, 
a dedicated effort is currently underway to identify the key in vivo substrates of individual MMPs [2, 4, 32] (Fig. 
2). 
The multiple functions of MMPs in cancer 
The recent identification of a large panel of matrix and non matrix substrates of MMPs revealed that aside their 
initial roles as ECM modulators, these proteases can regulate cellular physiology through several mechanisms. In 
early stages of cancer, the proteolytic processing of bioactive molecules contributes to the elaboration of a 
permissive microenvironment that promotes malignant transformation and tumor growth. MMP-3 can induce the 
expression of an alternative spliced form of Racl which causes an increase in cellular reactive oxygen species 
and genomic instability [33]. When bound, growth factors such as Transforming Growth Factor-β (TGFβ), 
insulin-like growth factor (IGF), Fibroblast Growth Factor (FGF) and Heparin Binding Epidermal Growth 
Factor-like growth factor (HB-EGF) are unable to interact with their receptor and to transduce a signal. Several 
MMPs control tumor cell proliferation by releasing growth factor bound to specific binding proteins or to matrix 
components. For instances, bioactive IGF is generated by the action of MMP-3 [34] or MMP-7 [35]. In addition, 
MMP-7 activates HB-EGF by cleaving its precursors anchored at the cell surface [36]. MT1-MMP confers a 
proliferative advantage to tumor cells when they are embedded in a 3D collagen-matrix [37]. Opposite effect on 
cell proliferation can be achieved by the shedding of growth factor receptors such as FGF receptor-1 (FGF-R1) 
[6, 38]. The cleavage of membrane bound Fas Ligand (mFasL) to soluble FasL (sFasL) by MMP-7 increases 
apoptosis in normal surrounding cells [39]. However, it permits tumor cells to escape from apoptosis [40, 41] 
since most cancer cells are relatively resistant to Fas-mediated apoptosis due to abnormalities in the signal 
transduction cascade [42]. Similarly, MMP-11 inhibits cancer cell death [43]. 
Loss of E-cadherin-mediated cell-cell adhesion is a prerequisite for tumor cell invasion and metastasis. 
Proteolytic degradation of E-cadherin by MMP-3 or MMP-7 is one of the mechanisms through which epithelial 
cell invasion is promoted by disrupting cell aggregation [44]. Proteolysis of E-cadherin and the release of free β 
catenin play a crucial role in epithelial to mesenchymal transition (EMT), a conversion of epithelial cells to an 
altered cellular phenotype which is associated with the acquisition of mesenchymal features and aggressive 
malignant behaviour [45, 46]. 
MMP-mediated degradation of ECM facilitates angiogenesis, tumor invasion and metastasis [7, 47]. Carcinoma 
cells were anticipated to produce by themselves proteolytic enzymes in order to degrade basement membrane for 
invading surrounding tissue. However, it is remarkable that individual tumor cells can cross ECM barriers 
through non proteolytic processes by exerting physical and mechanical forces that are capable of distorting 
matrix architecture [48]. Among several MMPs tested, only membrane-associated MMPs (MT1-MMP, MT2-
MMP and MT3-MMP) can serve as direct-acting proteases that are able of dissolving BM during cell migration 
[49]. MT1-MMP is a key enzyme in fibrillar collagen processing and its deletion in mice leads to severe 
connective tissue defect [25, 50]. Of interest is the recent finding that collective migration of human breast 
cancer cells and multicellular strand formation is controlled by MT1-MMP through ECM remodelling [51]. 
Importantly membrane-associated MT-MMPs focus proteolytic activity on specific sites on the cell surface that 
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are involved in cell migration [23, 28]. In addition to its fibrinolytic and collagenolytic activities, MT1-MMP 
stimulates cell motility through the processing of cell adhesion molecules CD44 [52, 53], integrin subunits (pro 
αv-integrin, β3 subunit) [54, 55] and tissue transglutaminase (tTG) [56]. It is also worth noting that MMP 
cleavage of ECM components such as laminin 5 or type IV collagen can expose cryptic sites that promote cell 
migration [57-59]. 
Fig. 1: Structure of MMPs. Matrilysins are the minimal-domain MMPs. They contain a signal peptide (Pre) for secretion 
and a propeptide (Pro) that maintains the enzyme in an inactive form by interacting with the Zinc binding site (Zinc) of the catalytic domain. 
Collagenases, stromelysins, metalloelastase, Enamelysin and MMP-27 are composed of these minimal domains and a hemopexin-like 
domain (hemopexin) connected to the catalytic domain with a hinge. The hemopexin domain allows the interaction with substrates and 
inhibitors. In addition of these domains, gelatinases display fibronec-tin   type   II   modules    (Fibronectin)   improving   collagen/gelatin 
degradation, and stromelysin-3, MMP-21, epilysin have a furin-like cleavage site allowing their intracellular activation. Membrane-Type 
MMPs (MT-MMPs) are linked to the cell membrane with either a transmembrane (TM) domain followed by a short cytoplasmic tail 
(Cytoplasmic) (MT1-, MT2-, MT3-, MT5-MMPs) or with a glyco-sylphosphatidyl-inositol (GPI) anchor (MT4- and MT6-MMPs). CA-MMP 
is a type II transmembrane MMP which is characterized by a N-terminal signal anchor (SA) targeting it to the membrane, a unique cysteine 
array (CA) and immunoglobulin-like (Ig-like) domains in C-terminal 
 
Several MMPs contribute to angiogenesis through different mechanisms [8, 28, 47, 60, 61]. They include at least 
the fibrinolytic activity [62], the collagenolytic activity [37], the morphogenesis of endothelial cell (tube 
formation or tubulogenesis) [63-65], the activation of αvβ3 integrin [66], the transcriptional regulation of 
Vascular Endothelial Growth Factor (VEGF) [67-69],  the release of VEGF sequestered in the ECM [70] or 
bound to connective tissue growth factor (CTGF) [71], the post-translational processing of VEGF [72], the mural 
cell investment through a control of PDGF receptor function and the recruitment of perivascular cells 
contributing to vessel stabilization [8, 73, 74]. The role of MMPs in angiogenesis is dual and complex, some 
MMPs acting as positive regulators (MMP-1, MMP-2, MMP-9, MT-MMPs) [8, 47, 70, 75, 76] and other as 
negative regulators (MMP-19) [77] sometimes involved in vessel regression (MMP-10) [61]. Abrogation of 
angiogenesis can rely on the production of protein fragments endowed with anti-angiogenic activities. For 
instances, degradation of ECM components (collagen types IV, XVIII) or plasminogen can generate angiogenic 
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Fig. 2: Implication of MMPs in cancer progression. MMPs are implicated in all steps of cancer progression including tumor 
growth, angiogenesis and metastases via the degradation of extracellular matrix (ECM) components, the release and/or activation of growth 
factors sequestrated in the matrix or complexed to associated proteins, the cleavage of cell surface receptors and the shedding of adhesion 
molecules. Although not indicated in this schematic representation, MMPs are also key regulators of the inflammatory reaction associated to 
cancer progression 
 
MMPs in human breast cancers 
With the aim of finding new powerful and earlier breast cancer prognostic bio-markers and new targets for 
cancer treatment, MMPs and MMP inhibitors (MMPIs), respectively, have been extensively investigated in 
human breast cancer clinical studies [80-82]. MMPs and TIMPs, are frequently overexpressed in human cancer 
tissues [15]. At least, MMP-1, -2, -9, -11, MT1-MMP, TIMP-1 and -2 levels have been largely investigated in 
breast cancer tissues by RT-PCR, immunohistochemistry, ELISA, in situ hybridization or zymography analyses 
(for a review see [80, 81, 83-88]). Despite some conflicting results regarding MMP-9 [89], in most of these 
studies, the tissue levels of MMPs and TIMPs have been correlated with poor outcome of breast cancer patients 
[81, 89, 90]. Additionally to their individual level of expression and activity, the ratio of MMP-2/TIMP-2 or 
MMP-9/TIMP-1, expected to reflect the proteolytic potential, has already been suggested as an early indicator of 
lymph-node metastases and prognosis [91, 92]. Regarding disease-free survival (DFS) and overall survival (OS) 
of breast cancer patients, MT1-MMP (MMP-14) mRNA [86, 93] but not protein levels [94, 95], stromal MMP-9 
but not tumoral protein expression [95], MMP-2 protein [96] and MMP-7 mRNA expression [97] seem to have 
an unfavourable prognostic significance. In sharp contrast, MMP-26 has been proposed as a favorable prognostic 
factor [98]. MMP and TIMP levels in body fluids such as blood and urine of breast cancer patients have been 
extensively assessed in many pathological processes [99, 100] including breast cancer [80]. Up to now, MMP-2, 
-7, -9, TIMP-1, -2 concentrations and MMP-2, -9 activities have been analyzed by ELISA and gelatin 
zymography or immuno-capture assay, respectively, in blood and urine of breast cancers patients [80]. Despite 
some divergent data, many of these studies have linked circulating MMPs or TIMPs with breast cancer presence, 
disease status, lymph-node metastasis or other clinicopathological parameters of patients suggesting their 
potential use in breast cancer screening, follow-up and risk of metastasis establishment. MMP-2 and MMP-9 
appear to have clinical value as diagnostic factors for breast cancer or predictive factors of metastases. In 
addition, proportions between the different forms or between MMPs and their tissue inhibitors (TIMPs), in term 
of concentration or activity could provide useful clinical information on breast cancer disease and classification 
[88, 101-104]. 
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Recently, the emphasis has been to reveal the gene expression signatures of primary tumors, which have been 
associated with their metastatic potential [105-107]. MMP-1 and MMP-9 are involved in the 70 genes 
identifying the "gene-expression signature" able to predict distant metastasis in lymph-node negative breast 
cancer patients [106]. Moreover, MMP-1 and MMP-2 have been described as genes that selectively mediate lung 
metastasis in a mouse model of breast cancer [107] and as members of a lung metastasis gene signature for 
human breast cancers [108]. Accordingly, MMP-1 has been identified as a useful marker to predict breast cancer 
development from ductal hyperplasia tissues by global gene expression analysis [109]. These data suggest that, 
in addition to their prognostic values, MMPs could be used as diagnostic factors to early predict breast lesions 
that may develop into cancer [80]. Interestingly, these global gene analyses have pinpointed the importance of 
stroma-derived genes [105, 108] and it is worth noting that peritumoral fibroblasts and inflammatory cells are 
mainly responsible for the production of tumor-associated MMPs, rather then tumor cells themselves. 
Peritumoral fibroblasts are the main producers of MMP-1 (interstitial collagenase), MMP-2, MMP-3 
(stromelysin-1), MMP-11 (stromelysin-3), MMP-13, MMP-14 in breast cancers [83, 86, 87, 110-112]. The 
expression of MMP-13 has been co-localized with that of MT1-MMP and MMP-2 suggesting their contribution 
in a proteolytic cascade [87], [113]. MMP-2 produced by fibroblasts can bind the cell surface of tumor cells 
through interaction with for instance MT1-MMP and integrin αvβ3 [87, 114, 115]. In this context, it is worth 
noting that in patients with invasive breast carcinomas, mRNA [93, 116-118] and membranous—but not 
cytoplasmic—protein expression levels of MT1-MMP [95, 119] have been correlated with lymph-node 
metastasis. 
MMPs in experimental models of breast cancer 
Several genetically engineered mouse models have been developed to mimic tumor initiation and progression 
processes of different types of cancer. These models allow a better understanding of cellular and molecular 
mechanisms underlying cancer progression and can provide useful information for anti-cancer drug development 
[120]. In breast cancer, these models consist in targeting the expression of oncogenes such as ErbB-2, Ras, Wnt1 
or the polyomavirus middle T antigen (PymT) in the mammary epithelium under the control of specific 
promoters including the mouse mammary tumor virus long terminal repeat (MMTV) and the whey acid protein 
(WAP) promoters [121]. The availability of these transgenic mice, together with others that are deficient for a 
specific MMP or that are overexpressing a MMP has been useful in attributing specific functions to individual 
MMPs in different steps of cancer progression [5, 6, 18]. Breast carcinogenesis can be achieved by crossing the 
transgenic mice lacking or over-expressing an MMP with mice expressing an oncogene in mammary glands, or 
by inducing mammary tumors chemically through the oral administration of 7,12-dim-ethylbenzanthracene 
(DMBA) [122]. 
Expression of MMP-3 and MT1-MMP in the mammary gland is sufficient to stimulate the development of 
invasive tumors [123, 124]. MMTV-MMP-3 and WAP-MMP-3 expressing mice display altered spontaneous or 
DMBA-induced tumor initiation [123, 125, 126]. Moreover, MMTV-MMP-7 expressing mice develop pre-
malignant nodules and increased oncogene-induced (MMTV-ErbB-2) mammary tumors. In contrast, mice 
lacking MMP-7 expression with a mutated Apc allele show a transient reduction of mammary tumors [127, 128]. 
The transgenic deficiency in MMP-2 or MMP-9 expression, the transgenic expression of TIMP-1 or -2 (MMTV-
TIMP) and the treatment with a MMPI are also reported to affect mammary tumorigenesis and lung metastases 
induced in MMTV-PymT or MMTV-Wntl models [122]. Altogether, these data implicate MMPs and their 
inhibitors in mammary tumor development. However, the situation is rendered even more complex by the fact 
that some MMPs appear to function as dual modulators of tumor progression. Indeed, MMP-11-deficient mice 
show a decreased DMBA-induced mammary carcinogenesis [129] and a decrease of tumor incidence/tumor 
growth [130]. However, MMP-11-/-/MMTV-ras mice develop more lung metastases than their wild type 
counterpart [130]. Therefore, MMP-11 function differs throughout cancer progression, it is an enhancer for 
primary tumor development, but a repressor for metastatic dissemination. 
Xenografts of human cancer cells transfected with one or other MMP cDNA is extensively used to investigate 
the behaviour of human cells in an in vivo environment. Indeed, different studies in which immunodeficient 
mice are injected with breast cancer cells over/down-expressing MMPs or TIMPs, demonstrate their implication 
in breast cancer progression and especially in development of metastases. Although most MMPs including for 
instance MMP-2 [131], MMP-11 [132, 133], MMP-3 [123], MT1-MMP [67, 134] and MT4-MMP [135] are 
generally positive regulators of cancer progression (tumor promoters), some of them such as MMP-8 [136] 
negatively regulate metastasis in breast cancer models. Similarly, as mentioned above, MMP-11 represses 
metastatic dissemination, while it enhances primary tumor development [130]. These opposite tumor/metastasis-
promoting effects of different MMPs or of the same MMP at different stages of cancer progression is one of the 
explanations why clinical trials of broad spectrum MMP inhibitors have failed, underlining the importance to 
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develop more specific inhibitors of MMPs. 
Since fibroblasts constitute the majority of stromal cells within a breast carcinoma and since they are a primary 
source of MMP, a co-implantation tumor xenograft model has been used to investigate the interplay between 
fibroblasts and breast carcinoma cells [10, 137]. The tumor promoting effect of fibroblasts in xenografts is 
blocked by TIMP2 or synthetic MMP inhibitor [137, 138]. Interestingly, MMP-11-null fibroblasts [129] or MT1-
MMP-null fibroblasts [139] do not support in vivo growth of tumor cells whereas corresponding wild-type 
fibroblasts enhance tumor development. MMP-11 is a stromal factor which promotes the primary implantation of 
cancer cells in an aberrant environment [110]. In MMP-11-deficient mice, the number of apoptotic cancer cells is 
increased in primary tumors, indicating that host MMP-11 helps tumor cells in escaping apoptosis [43]. 
Cancer cells can stimulate fibroblasts to synthesize MMPs in a paracrine manner through the secretion of 
interleukins, interferons, growth factors and Extracellular Matrix Metalloproteinase Inducer (EMMPRΓN) [19, 
140, 141]. The pathologic consequence of elevated EMMPRIN is supported by the accelerated growth and 
increased invasiveness exhibited by breast cancer cells overexpressing EMMPRIN [23, 142]. Interestingly, 
carcinoma-associated fibroblasts (CAF)s extracted from human breast carcinomas are better promoters of human 
breast adenocarcinoma cell growth in xenograft than normal primary fibroblasts derived from the same patient 
[143]. It is worth noting that the upregulation of MMPs is one of the physiological changes that occur when 
fibroblasts undergo senescence. This likely promotes the generation of a pro-oncogenic microenvironment that 
contributes to the increased incidence of cancers observed with age [144, 145]. Accordingly, fibroblasts that 
have been forced into senescence by DNA damage increased the growth of cancer cells in a MMP-dependent 
manner [145]. The tumor microenvironment can be a potent carcinogen, not only by facilitating cancer 
progression, but also by stimulating tumor formation. A stromal enzyme such as MMP-3 can cause sustained 
EMT and malignant transformation in cultured cells and genomically unstable mammary carcinomas in 
transgenic mice [33, 123]. 
Conclusions 
Based on the fact that MMPs were initially viewed as invasion-associated proteases, preclinical studies of MMP 
inhibition were performed in different mouse cancer models. The success of these studies led to the rapid 
development of synthetic MMP inhibitors (MMPIs) and their assessment in clinical trials. However, the results 
obtained in phase III trials were disappointing with many adverse side effects [15, 18, 140, 146, 147]. The failure 
of MMP inhibition in cancer therapy is now better understood [146, 148]. One explanation, among others, is that 
clinical trials have been performed in advanced stages of cancers whereas MMPs are more expected to play 
crucial role in early steps of cancer progression. In addition, broad spectrum MMPI block the activity of all 
metalloproteases (including ADAMs and ADAMTS) and it is now well known that different MMPs can have 
opposite effects or different effects at different stage of cancer progression. Therefore, some MMPs are viewed 
as "drug targets", while others are considered as "anti-targets" for cancer therapy [17]. The initial concept of 
MMPs as simple modulators of ECM remodeling has been replaced by the consideration of MMPs as 
multifaceted proteases able to tightly control the biodisponibility and activity of a large panel of proteins. In 
addition, it is possible that substrates and products of MMPs could be preferred as targets for treating cancer 
rather than MMPs themselves. However, such strategies depend on better knowledge on how individual MMPs 
are contributing to tumor growth and metastatic dissemination. In this context, the complementarity between 
human clinical studies and mouse models is of great importance. 
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